Small molecule drug developer Synta Pharmaceuticals Corp. (SNTA) Thursday reported a lower loss for the fourth quarter, helped by a one-time acceleration of deferred revenue related to a former partnership agreement.
Lexington, Massachusetts-based Synta Pharma's net loss for the quarter narrowed to $7.04 million or $0.21 per share from $25.95 million or $0.77 per share in the same quarter a year ago.
On average, four analysts polled by Thomson Reuters expected a loss of $0.25 per share for the quarter. Analysts' estimate typically excludes one-time items.
Synta recognized total collaboration revenue of $4.68 million, higher than $0.64 million in the prior-year quarter and better than Street expectation of $4.13 million.
Revenues rose helped by a one-time acceleration of around $114.6 million of deferred revenue from upfront payments and milestones received under the GSK Agreement, which was terminated effective September 2009.
Research and development expenses were $9.23 million, down compared to $23.03 million in the year-earlier quarter. Total operating expenses were $11.66 million, compared to $25.87 million in the prior-year quarter.
Loss from operations was $6.98 million, compared to loss of $25.87 million in the corresponding quarter last year.
As of December 31, 2009, the company had $44.2 million in cash and cash equivalents and also raised $26.7 million of net proceeds from the sale of its common stock in an underwritten public offering in January 2010. This compares to $73.6 million in cash, cash equivalents and marketable securities as of December 31, 2008.
For the full year 2009, net profit was $79.09 million or $2.32 per share, compared to a loss of $92.62 million or $2.75 per share a year ago. Total collaboration revenue was $144.25 million, including the one-time acceleration of deffered revenue, compared to $2.62 million in the prior year. Street analysts' expected earnings of $2.23 per share on revenues of $143.02 million for the year.
"Our primary goals for 2010 are focused on advancing the clinical development of STA-9090: reporting initial data from each of our six ongoing trials, initiating six to ten new trials, and enabling the initiation of one or more pivotal studies for STA-9090 next year," said Safi Bahcall, Ph.D., President and Chief Executive Officer of Synta.
STA-9090 is a HSP90 inhibitor under development by the company currently in Phase 2 clinical study in patients with advanced gastrointestinal stromal tumors.
SNTA closed Wednesday's regular trading at $4.53, down $0.07, on a volume of 0.21 million shares.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.